[Skip to Content]
[Skip to Content Landing]
Views 513
Citations 0
Invited Commentary
December 2018

MUC16 Mutations and Prognosis in Gastric Cancer: A Little Goes a Long Way

Author Affiliations
  • 1Department of Gastrointestinal Oncology and Lymphoma, Royal Marsden Hospital, London and Sutton, London, United Kingdom
  • 2Now with Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
  • 3MRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, United Kingdom
JAMA Oncol. 2018;4(12):1698-1699. doi:10.1001/jamaoncol.2018.2803

Gastric cancer is a global health problem; although incidence rates are declining, it remains the third most common cause of cancer death worldwide. Patients with advanced disease have limited treatment options, and most will live for less than 2 years. Therefore, exploration of gastric cancer disease biology is warranted to identify new targets for treatment. Recent comprehensive molecular analyses have identified distinct subgroups of gastric cancer that may have therapeutic relevance. With the exception of microsatellite-unstable tumors, however, the potential for genomically guided therapy has not been realized.

×